Intraperitoneal chemotherapy in patients with optimally debulked ovarian cancer – The Westmead Hospital experience — YRD
  1. Schedule
  2. Session 6
  3. Intraperitoneal chemotherapy in patients with optimally debulked ovarian cancer – The Westmead Hospital experience

Intraperitoneal chemotherapy in patients with optimally debulked ovarian cancer – The Westmead Hospital experience (2725)

Christina Girgis 1 , Alison Brand 2 , Gerard Wain 2 , Russell Hogg 2 , Paul Harnett 1 , Kristina Lindemann 1
  1. Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, NSW, Australia
  2. Department of Gynaecological Oncology, Westmead Hospital, Westmead, NSW, Australia

Objectives: To evaluate clinical outcomes and tolerability of IP chemotherapy in ovarian cancer patients.

Methods: A retrospective review was conducted of all patients from 2006 and 2015 with optimally debulked ovarian cancer (≤1cm residual disease) in whom IP chemotherapy was planned. 

Results: 64 patients with a median age of 54.5 years were included. 80.6% had Stage III/IV disease. 56.3% had no macroscopic residual disease after surgery. 62 patients received ≥1 cycle of IP chemotherapy (mean 4.1). Half completed their intended IP treatment. The main reasons for non-completion were port-related (32.8%). After median follow-up of 50.5 months,  55% had disease recurrence and 39% had died. Median progression free survival was 25 months. Median overall survival was 57 months.

Conclusion: IP chemotherapy was generally well-tolerated and showed good overall clinical outcomes, in keeping with those reported in the literature. Initially, catheter-related  problems  rather than toxicity resulted in a switch to intravenous chemotherapy.